Oramed Pharmaceuticals (ORMP) Other financing activities (2019 - 2025)

Oramed Pharmaceuticals (ORMP) posted Other financing activities of $500000.0 for Q1 2025, up 2400.0% on a QoQ basis from $20000.0 in Q4 2022.

Oramed Pharmaceuticals (ORMP) Other financing activities (2019 - 2025) Analysis & Trends

Oramed Pharmaceuticals' Other financing activities history runs 4 years deep, the most recent figure standing at $500000.0 for Q1 2025.

Quarterly Other financing activities changed N/A year-over-year to $500000.0 in Q1 2025, while the trailing twelve-month figure through Sep 2025 was $520000.0 (changed N/A YoY) and the FY2022 annual result came in at $62000.0, changed N/A from the prior year.
Other financing activities was $500000.0 for Q1 2025 at Oramed Pharmaceuticals, up from $20000.0 in the prior quarter.
Across five years, Other financing activities topped out at $500000.0 in Q1 2025 and bottomed at $20000.0 in Q4 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	66,741.39 Bn	66,741.11 Bn	-
2	Nanobiotix	1,935.05 Bn	1,934.98 Bn	-
3	Akari Therapeutics	1,045.06 Bn	1,045.06 Bn	-
4	BeOne Medicines	468.98 Bn	464.19 Bn	1.35 Bn
5	Vertex Pharmaceuticals	123.24 Bn	115.99 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	70.45 Bn	61.70 Bn	3.31 Bn
7	Belite Bio	63.04 Bn	63.04 Bn	-
8	Argenx Se	55.79 Bn	50.60 Bn	1.41 Bn
9	Alnylam Pharmaceuticals	37.79 Bn	34.78 Bn	959.66 Mn
10	Oramed Pharmaceuticals	167.58 Mn	167.58 Mn	-

Download Data